This study substantiates the key contribution of inflammatory markers (i.e., TNF-α) in combination with plasma Aβ1−42 levels and increased proNGF levels to better predict the worsening of “latent” AD pathology with the consequential cognitive decline in Down syndrome patients (115). The gene discussed is TNF; the disease is Alzheimer disease.